羅妥木單抗
外觀
單株抗體 | |
---|---|
種類 | 完整抗體 |
目標 | CD221 |
臨床資料 | |
ATC碼 |
|
識別資訊 | |
CAS號 | 934235-44-6 ![]() |
ChemSpider |
|
UNII | |
KEGG | |
化學資訊 | |
化學式 | C6418H9960N1732O1992S42 |
摩爾質量 | 144,602.93 g·mol−1 |
羅妥木單抗(INN:Robatumumab;開發代號:SCH 717454和MK-7454)是默克和先靈葆雅生產的單株抗體和抗腫瘤藥物。它與CD221(或稱胰島素樣生長因子1受體)結合。[1]
針對結直腸癌、骨肉瘤和尤文氏肉瘤患者的II期臨床試驗已經完成。[2][3]此後默克公司停止了該藥物的開發。[4]
參考資料
[編輯]- ^ "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines. Encrenaz C , 編. Proposed International Nonproprietary Names: List 100 (PDF). WHO Drug Information. 2008, 22 (4): 311–67 [2024-01-24]. (原始內容存檔 (PDF)於2022-01-20).
- ^ Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatric Blood & Cancer. October 2016, 63 (10): 1761–70. PMC 5129487
. PMID 27362300. doi:10.1002/pbc.26087.
- ^ Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov
- ^ Robatumumab. Adis Insight. Springer Nature Switzerland AG. [2024-01-24]. (原始內容存檔於2024-01-24).
|